CYT Key Statistics, Chart & Performance
The current stock price of CYT is 3.02 USD. In the past month the price decreased by -2.89%. In the past year, price increased by 81.93%.
CYT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYT. When comparing the yearly performance of all stocks, CYT is one of the better performing stocks in the market, outperforming 90.36% of all stocks.
CYT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYT. CYT has a great financial health rating, but its profitability evaluates not so good.
CYT Financial Highlights
Over the last trailing twelve months CYT reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 31.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.35% | ||
| ROE | -26.57% | ||
| Debt/Equity | 0 |
CYT Forecast & Estimates
8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.
CYT Ownership
About CYT
Company Profile
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
Company Info
CYTEIR THERAPEUTICS INC
99 Hayden Avenue, Building B, Suite 450
Lexington MASSACHUSETTS US
CEO: Markus Renschler
Employees: 46
Phone: 18572854140
CYTEIR THERAPEUTICS INC / CYT FAQ
Can you describe the business of CYTEIR THERAPEUTICS INC?
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
What is the stock price of CYTEIR THERAPEUTICS INC today?
The current stock price of CYT is 3.02 USD. The price decreased by -2.27% in the last trading session.
What is the dividend status of CYTEIR THERAPEUTICS INC?
CYT does not pay a dividend.
What is the ChartMill rating of CYTEIR THERAPEUTICS INC stock?
CYT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CYTEIR THERAPEUTICS INC (CYT)?
CYTEIR THERAPEUTICS INC (CYT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.3).
What is CYTEIR THERAPEUTICS INC worth?
CYTEIR THERAPEUTICS INC (CYT) has a market capitalization of 108.72M USD. This makes CYT a Micro Cap stock.